Skip To Main Content
Steven Knapper on Muck Rack

Steven Knapper

As seen in: Nature, Wiley Online Library
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Steven Knapper’s profile

Articles by Steven Knapper

Tamoxifen for the treatment of myeloproliferative neoplasms: A Phase II clinical trial and exploratory analysis - Nature Communications

|
By Thomas McKerrell, Dorian Forte, Hannah R. Bridges, Adam Mead, Steven Knapper, Judy Hirst, E. Baxter, Jose-Ezequiel Martin, Mary F. McMullin, Maike Paramor
| Nature Verified
Abstract Current therapies for myeloproliferative neoplasms (MPNs) improve symptoms but have limited effect on tumor size. In preclinical studies, tamoxifen restored normal apoptosis in mutated hematopoietic stem/progenitor cells (HSPCs). TAMARIN Phase-II, multicenter, single-arm clinical trial assessed tamoxifen’s safety and activity in patients with stable MPNs, no prior thrombotic events and mutated JAK2V617F, CALRins5 or CALRdel52 peripheral blood allele burden ≥20% (EudraCT 2015-005497-38).
Open in Who Shared Issue with article?

FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML - Leukemia

|
By Jad Othman, Charles Craddock, Sylvie D. Freeman, Steven Knapper, Mary Frances McMullin, Marianne Tang Severinsen
| Nature Verified
Abstract Patients with FLT3-mutated AML have a high relapse rate and suboptimal outcomes. Many have co-mutations suitable for measurable residual disease (MRD) monitoring by RT-qPCR and those destined to relapse can be identified by high or rising levels of MRD, called molecular failure. This provides a window for pre-emptive intervention, but there is little evidence to guide treatment. The use of FLT3 inhibitors (FLT3i) appears attractive but their use has not yet been evaluated.
Open in Who Shared Issue with article?
Show More